---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-25-004186"
form_type: "8-K"
ticker: "BCRX"
cik: "0000882796"
company_name: "BIOCRYST PHARMACEUTICALS INC"
filed_at: "2025-06-27T23:59:59+00:00"
generated_at: "2026-05-18T17:11:17.701260+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# BioCryst sells European ORLADEYO rights to Neopharmed Gentili for up to $264M

## Summary
- Neopharmed Gentili pays $250M upfront, up to $14M milestones; closing expected by early October 2025.
- Proceeds to retire all $249M remaining term debt, eliminating ~$70M future interest payments.
- BioCryst now expects ~$700M cash and no term debt by end 2027, a $400M increase from prior guidance.
- Sale includes European team; BioCryst saves at least $50M in annual operating expenses.
- European ORLADEYO revenues still count toward global royalty tiers for OMERS and >$550M cap.

## SEC filing metadata
- accession: 0001171843-25-004186
- form_type: 8-K
- ticker: BCRX
- cik: 0000882796
- company_name: BIOCRYST PHARMACEUTICALS INC
- filed_at: 2025-06-27T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/882796/000117184325004186/0001171843-25-004186-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/882796/000117184325004186/f8k_062725.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-25-004186
- JSON: https://secwatch.observer/filing/0001171843-25-004186.json
- Plain text: https://secwatch.observer/filing/0001171843-25-004186.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.